标题
Novel therapeutic targets for cholestatic and fatty liver disease
作者
关键词
-
出版物
GUT
Volume 71, Issue 1, Pages 194-209
出版商
BMJ
发表日期
2021-10-22
DOI
10.1136/gutjnl-2021-324305
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
- (2021) Jörn M. Schattenberg et al. JOURNAL OF HEPATOLOGY
- A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis
- (2021) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Real-World Clinical Management of Patients with Primary Biliary Cholangitis—A Retrospective Multicenter Study from Germany
- (2021) Anne-Christin Beatrice Wilde et al. Journal of Clinical Medicine
- Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double‐Blind Phase 2 Trial
- (2021) Samer Gawrieh et al. HEPATOLOGY
- Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis
- (2021) Maria Reich et al. JOURNAL OF HEPATOLOGY
- A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis
- (2021) Raj Vuppalanchi et al. Clinical and Translational Gastroenterology
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
- (2021) Rajaa Nahra et al. DIABETES CARE
- Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
- (2021) Stephen A. Harrison et al. NATURE MEDICINE
- Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges
- (2020) Sander Lefere et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals novel therapeutic opportunities
- (2020) Benjamin Goeppert et al. HEPATOLOGY
- Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
- (2020) Vlad Ratziu et al. HEPATOLOGY
- Monocytes as potential mediators of pathogen‐induced Th17 differentiation in patients with primary sclerosing cholangitis (PSC)
- (2020) Lilly Kristin Kunzmann et al. HEPATOLOGY
- Thyroid hormones and thyromimetics: A new approach to NASH?
- (2020) Rohit Anthony Sinha et al. HEPATOLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials
- (2020) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
- (2020) Mark L. Hartman et al. DIABETES CARE
- Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
- (2020) Jean-François Dufour et al. GUT
- Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis
- (2020) Wei Chen et al. HEPATOLOGY
- The role of metabolic lipases in the pathogenesis and management of liver disease
- (2020) Matteo Tardelli et al. HEPATOLOGY
- Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities
- (2020) Mette Vesterhus et al. JOURNAL OF GASTROENTEROLOGY
- A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
- (2020) Kris V. Kowdley et al. JOURNAL OF HEPATOLOGY
- Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
- (2020) Philip N. Newsome et al. JOURNAL OF HEPATOLOGY
- Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults
- (2020) Albert Friedrich Stättermayer et al. JOURNAL OF HEPATOLOGY
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
- (2020) Stephen A. Harrison et al. GASTROENTEROLOGY
- A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Novel Drivers of Disease Progression in Primary Sclerosing Cholangitis
- (2020) Yevgeniy Gindin et al. HEPATOLOGY
- Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders
- (2020) Saul J. Karpen et al. Hepatology International
- Design and Structural Optimization of Dual FXR/PPARδ Activators
- (2020) Simone Schierle et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cholangiocarcinoma 2020: the next horizon in mechanisms and management
- (2020) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- The Emerging Role of Macrophages in Chronic Cholangiopathies Featuring Biliary Fibrosis: An Attractive Therapeutic Target for Orphan Diseases
- (2020) Massimiliano Cadamuro et al. Frontiers in Medicine
- Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double blind, randomized, placebo-controlled trial
- (2020) Elsemieke de Vries et al. GASTROENTEROLOGY
- The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in Nonalcoholic Steatohepatitis
- (2020) Rohit Loomba et al. HEPATOLOGY
- A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA
- (2020) G.M. Hirschfield et al. JOURNAL OF HEPATOLOGY
- Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
- (2020) Sven Francque et al. Nature Reviews Gastroenterology & Hepatology
- Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
- (2020) Stefan Traussnigg et al. WIENER KLINISCHE WOCHENSCHRIFT
- Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
- (2020) Zoe Boyer-Diaz et al. JOURNAL OF HEPATOLOGY
- FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
- (2020) Erik J. Tillman et al. Frontiers in Endocrinology
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
- (2020) Rohit Loomba et al. HEPATOLOGY
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Markers of Cholestatic Liver Injury in Patients With Primary Biliary Cholangitis Treated With Obeticholic Acid and Bezafibrate
- (2020) Lena Smets et al. HEPATOLOGY
- The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC
- (2019) Michael Trauner et al. HEPATOLOGY
- Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis
- (2019) Nobuhiro Nakamoto et al. Nature Microbiology
- NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis
- (2019) Stephen A. Harrison et al. HEPATOLOGY
- Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis
- (2019) Akira Honda et al. HEPATOLOGY
- Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis
- (2019) Jessica R. Allegretti et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Cholangiocyte‐Derived Exosomal Long Noncoding RNA H19 Promotes Hepatic Stellate Cell Activation and Cholestatic Liver Fibrosis
- (2019) Runping Liu et al. HEPATOLOGY
- The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
- (2019) Arun J. Sanyal et al. HEPATOLOGY
- LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial
- (2019) Rohit Loomba et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study
- (2019) John E. Eaton et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice
- (2019) Daniel Lindén et al. Molecular Metabolism
- Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
- (2019) Jonathan D. Roth et al. Scientific Reports
- FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
- (2019) Aroosha Raja et al. Cells
- Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study
- (2019) Michael Trauner et al. Lancet Gastroenterology & Hepatology
- Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
- (2019) Stefan Traussnigg et al. Lancet Gastroenterology & Hepatology
- Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
- (2019) Rohit A. Sinha et al. THYROID
- Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis
- (2019) Christopher L. Bowlus et al. Clinical Gastroenterology and Hepatology
- Clinical Management of Primary Biliary Cholangitis—Strategies and Evolving Trends
- (2019) Lixia Gao et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies
- (2019) Marica Meroni et al. Nutrients
- Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae
- (2019) Jing Yuan et al. Cell Metabolism
- New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases
- (2019) Sara Lemoinne et al. CURRENT OPINION IN PHARMACOLOGY
- The Spectrum of Reactive Cholangiocytes in Primary Sclerosing Cholangitis
- (2019) Maria Eugenia Guicciardi et al. HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression
- (2019) Fabián Segovia-Miranda et al. NATURE MEDICINE
- Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis
- (2018) J. L. Damman et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
- (2018) Juan Pablo Arab et al. Annual Review of Pathology-Mechanisms of Disease
- Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists
- (2018) Gwilym James Webb et al. Clinical Gastroenterology and Hepatology
- Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated With Nonalcoholic Steatohepatitis and Fibrosis
- (2018) Donghee Kim et al. Clinical Gastroenterology and Hepatology
- The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease
- (2018) Puneet Puri et al. Clinics in Liver Disease
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- Colesevelam attenuates cholestatic liver and bile duct injury inMdr2−/−mice by modulating composition, signalling and excretion of faecal bile acids
- (2018) Claudia Daniela Fuchs et al. GUT
- Na+ -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice
- (2018) Davor Slijepcevic et al. HEPATOLOGY
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
- (2018) Kris V. Kowdley et al. HEPATOLOGY
- Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD
- (2018) Eveline Bruinstroop et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: An interim analysis of an ongoing phase 2 study
- (2018) C. Schramm et al. JOURNAL OF HEPATOLOGY
- Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice
- (2018) Maria Eugenia Guicciardi et al. JOURNAL OF HEPATOLOGY
- Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis
- (2018) Marion J. Pollheimer et al. JOURNAL OF HEPATOLOGY
- FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver
- (2018) Romeo Papazyan et al. JOURNAL OF LIPID RESEARCH
- Thyroid hormone receptor β1 stimulates ABCB4 to increase biliary phosphatidylcholine excretion in mice
- (2018) Julien Gautherot et al. JOURNAL OF LIPID RESEARCH
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK
- (2018) Roger Williams et al. LANCET
- Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents
- (2018) Dongke Yu et al. LIVER INTERNATIONAL
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
- (2018) Christophe Corpechot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide
- (2018) Manabu Kaneko et al. Scientific Reports
- Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease
- (2018) Andrew J. Muir et al. HEPATOLOGY
- Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- (2018) Zobair Younossi et al. HEPATOLOGY
- Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
- (2018) Maurizio Parola et al. MOLECULAR ASPECTS OF MEDICINE
- Anti-Obesity Therapy: from Rainbow Pills to Polyagonists
- (2018) T. D. Müller et al. PHARMACOLOGICAL REVIEWS
- PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC
- (2018) Beata Kruk et al. PLoS One
- Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French–Spanish experience
- (2018) Sara Lemoinne et al. Clinics and Research in Hepatology and Gastroenterology
- FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid
- (2018) Elliot S. Friedman et al. GASTROENTEROLOGY
- The Role of PPAR-δ in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor
- (2018) Yi Liu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis
- (2018) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial
- (2018) Gideon M. Hirschfield et al. JOURNAL OF HEPATOLOGY
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Role of TGR5 (GPBAR1) in Liver Disease
- (2018) Dieter Häussinger et al. SEMINARS IN LIVER DISEASE
- Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis
- (2018) Raffaella Maria Gadaleta et al. Scientific Reports
- Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease
- (2017) Oscar Chávez-Talavera et al. GASTROENTEROLOGY
- Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy
- (2017) Ruqi Tang et al. GUT
- Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD
- (2017) Na Jiao et al. GUT
- The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells
- (2017) Francesca Virginia Bruschi et al. HEPATOLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- New therapeutic concepts in bile acid transport and signaling for management of cholestasis
- (2017) Michael Trauner et al. HEPATOLOGY
- The ascending pathophysiology of cholestatic liver disease
- (2017) Peter L.M. Jansen et al. HEPATOLOGY
- Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects
- (2017) Vanessa Legry et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Distinct but complementary contributions of PPAR isotypes to energy homeostasis
- (2017) Vanessa Dubois et al. JOURNAL OF CLINICAL INVESTIGATION
- EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
- (2017) Gideon M. Hirschfield et al. JOURNAL OF HEPATOLOGY
- nor Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
- (2017) Peter Fickert et al. JOURNAL OF HEPATOLOGY
- Primary sclerosing cholangitis – a comprehensive review
- (2017) Tom H. Karlsen et al. JOURNAL OF HEPATOLOGY
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2017) David C. Tully et al. JOURNAL OF MEDICINAL CHEMISTRY
- Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD
- (2017) Valerio Nobili et al. LIVER INTERNATIONAL
- Inflammation, metaflammation and immunometabolic disorders
- (2017) Gökhan S. Hotamisligil NATURE
- Mechanisms of hepatic stellate cell activation
- (2017) Takuma Tsuchida et al. Nature Reviews Gastroenterology & Hepatology
- The Microbiome in Primary Sclerosing Cholangitis: Current Evidence and Potential Concepts
- (2017) Johannes Hov et al. SEMINARS IN LIVER DISEASE
- Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP
- (2017) Joanne M. Donkers et al. Scientific Reports
- Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis
- (2017) Giovanni Musso et al. JAMA Internal Medicine
- Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers
- (2016) Annarosa Floreani et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?
- (2016) Swetha Rudraiah et al. Annual Review of Pharmacology and Toxicology
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- An Intestinal Microbiota–Farnesoid X Receptor Axis Modulates Metabolic Disease
- (2016) Frank J. Gonzalez et al. GASTROENTEROLOGY
- Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
- (2016) Juan P. Arab et al. HEPATOLOGY
- Hepatitis B virus receptors and molecular drug targets
- (2016) Eloi R. Verrier et al. Hepatology International
- Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis
- (2016) Anna Baghdasaryan et al. JOURNAL OF HEPATOLOGY
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis
- (2016) Petra Hirsova et al. JOURNAL OF LIPID RESEARCH
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
- (2016) Frederik Nevens et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet–fed mice
- (2016) Anuradha Rao et al. Science Translational Medicine
- Primary Biliary Cirrhosis Beyond Ursodeoxycholic Acid
- (2016) Christophe Corpechot SEMINARS IN LIVER DISEASE
- Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease
- (2016) Claudia Fuchs et al. SEMINARS IN LIVER DISEASE
- Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis
- (2016) Natalia Gomez-Ospina et al. Nature Communications
- Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes
- (2015) A. C. Cheung et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Homeostasis, Inflammation, and Disease Susceptibility
- (2015) Maya E. Kotas et al. CELL
- Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice
- (2015) Magdalena Mazagova et al. FASEB JOURNAL
- Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
- (2015) Gideon M. Hirschfield et al. GASTROENTEROLOGY
- Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis
- (2015) James H. Tabibian et al. HEPATOLOGY
- Fibrates and cholestasis
- (2015) Nisanne S. Ghonem et al. HEPATOLOGY
- Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice
- (2015) Alexander G. Miethke et al. HEPATOLOGY
- Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na+-taurocholate cotransporting polypeptide knockout mice
- (2015) Davor Slijepcevic et al. HEPATOLOGY
- Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2 -deficient mice
- (2015) Mei Zhou et al. HEPATOLOGY
- Genetics of liver disease: From pathophysiology to clinical practice
- (2015) Tom H. Karlsen et al. JOURNAL OF HEPATOLOGY
- Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
- (2015) Michaela Mueller et al. JOURNAL OF HEPATOLOGY
- New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond
- (2015) Ulrich Beuers et al. JOURNAL OF HEPATOLOGY
- Hepatic fibrosis: Concept to treatment
- (2015) Christian Trautwein et al. JOURNAL OF HEPATOLOGY
- Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
- (2015) Michal Pawlak et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Large-scale whole-genome sequencing of the Icelandic population
- (2015) Daniel F Gudbjartsson et al. NATURE GENETICS
- Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
- (2015) Sungsoon Fang et al. NATURE MEDICINE
- Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
- (2015) Chiara Degirolamo et al. NATURE REVIEWS DRUG DISCOVERY
- Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
- (2015) Changtao Jiang et al. Nature Communications
- Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis
- (2015) Alla Y. Grigorian et al. Clinics and Research in Hepatology and Gastroenterology
- Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
- (2014) M. Zhou et al. CANCER RESEARCH
- Interactions Between the Intestinal Microbiome and Liver Diseases
- (2014) Bernd Schnabl et al. GASTROENTEROLOGY
- Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype
- (2014) Frédéric M. Vaz et al. HEPATOLOGY
- Saturated free fatty acids induce cholangiocyte lipoapoptosis
- (2014) Sathish Kumar Natarajan et al. HEPATOLOGY
- A nontumorigenic variant of FGF19 treats cholestatic liver diseases
- (2014) J. Luo et al. Science Translational Medicine
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
- (2013) Shin Yoshimoto et al. NATURE
- A Frequent PNPLA3 Variant Is a Sex Specific Disease Modifier in PSC Patients with Bile Duct Stenosis
- (2013) Kilian Friedrich et al. PLoS One
- Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome
- (2012) Anne Vrieze et al. GASTROENTEROLOGY
- TGR5 potentiates GLP-1 secretion in response to anionic exchange resins
- (2012) Taoufiq Harach et al. Scientific Reports
- Identical Gene Regulation Patterns of T3and Selective Thyroid Hormone Receptor Modulator GC-1
- (2011) Chaoshen Yuan et al. ENDOCRINOLOGY
- Alterations in Lipid Metabolism Mediate Inflammation, Fibrosis, and Proliferation in a Mouse Model of Chronic Cholestatic Liver Injury
- (2011) Tarek Moustafa et al. GASTROENTEROLOGY
- Farnesoid X Receptor Agonist for the Treatment of Liver and Metabolic Disorders: Focus on 6-ethyl-CDCA
- (2011) S. Fiorucci et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Lysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus
- (2010) Andreas E. Kremer et al. GASTROENTEROLOGY
- Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches
- (2010) Gideon M. Hirschfield et al. GASTROENTEROLOGY
- Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation
- (2010) A. Baghdasaryan et al. GUT
- Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues
- (2010) Vlad Ratziu et al. HEPATOLOGY
- High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial
- (2010) Ulrich F. H. Leuschner et al. HEPATOLOGY
- Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites
- (2010) Brent A. Neuschwander-Tetri HEPATOLOGY
- The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation
- (2010) Thijs W.H. Pols et al. JOURNAL OF HEPATOLOGY
- A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
- (2010) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nuclear receptors as therapeutic targets in cholestatic liver diseases
- (2009) Gernot Zollner et al. BRITISH JOURNAL OF PHARMACOLOGY
- Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice
- (2009) Emina Halilbasic et al. HEPATOLOGY
- Hepatocyte-specific NEMO deletion promotes NK/NKT cell– and TRAIL-dependent liver damage
- (2009) Naiara Beraza et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The new therapeutic frontier – Nuclear receptors and the liver
- (2009) Saul J. Karpen et al. JOURNAL OF HEPATOLOGY
- Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease
- (2009) Marina G. Silveira et al. LIVER INTERNATIONAL
- Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
- (2009) Philippe Lefebvre et al. PHYSIOLOGICAL REVIEWS
- Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study
- (2008) Frank P. Vleggaar et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis
- (2008) M Marzioni et al. GUT
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
- (2008) Yan-Dong Wang et al. HEPATOLOGY
- Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
- (2008) Stefano Romeo et al. NATURE GENETICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started